176 related articles for article (PubMed ID: 36669842)
1. Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study.
Guan Y; Qi Y; Zheng L; Yang J; Zhang M; Zhang Q; Ji L
BMJ Open; 2023 Jan; 13(1):e068127. PubMed ID: 36669842
[TBL] [Abstract][Full Text] [Related]
2. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
3. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
4. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
5. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
Sakaeda T; Kadoyama K; Minami K; Okuno Y
Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
[TBL] [Abstract][Full Text] [Related]
6. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
7. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
Wen H; Lu C; Zhang M; Qi X
Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
9. Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database.
Wang Q; Qu K; Du Z; Shen Y; Jiang Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):562-566. PubMed ID: 38641957
[TBL] [Abstract][Full Text] [Related]
10. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
12. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.
Kim S; Park K; Kim MS; Yang BR; Choi HJ; Park BJ
Psychiatry Res; 2017 Oct; 256():237-242. PubMed ID: 28646789
[TBL] [Abstract][Full Text] [Related]
13. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
[TBL] [Abstract][Full Text] [Related]
14. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
Ang PS; Chen Z; Chan CL; Tai BC
Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
[TBL] [Abstract][Full Text] [Related]
15. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
[TBL] [Abstract][Full Text] [Related]
16. Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database.
Tian X; Yao Y; He G; Jia Y; Wang K; Chen L
Sci Rep; 2021 Jun; 11(1):12438. PubMed ID: 34127681
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
18. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
[TBL] [Abstract][Full Text] [Related]
19. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
[TBL] [Abstract][Full Text] [Related]
20. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China.
Li C; Xia J; Deng J; Jiang J
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):593-600. PubMed ID: 18432629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
